
Peoples Bancorp Q3 profit rises to $32.6 million
- Peoples Bancorp reported third-quarter 2026 net income of $32.6 million, exceeding both the previous quarter and the year-earlier period, while diluted earnings increased to $0.91 per share.
- Net interest income reached $93.8 million, and net interest margin improved to 4.31% from 4.23%, supported by a lower provision for credit losses.
- Peoples is pursuing the acquisitions of Citizens National Corporation for approximately $76.6 million and Capital Bancorp for approximately $728.1 million, subject to applicable closing conditions.
Peoples Bancorp (NASDAQ:PEBO) reported third-quarter 2026 net income of $32.6 million, with diluted earnings of $0.91 per share.
Diluted earnings increased from $0.78 in the second quarter and $0.83 a year earlier, while credit-loss provisions declined sequentially.
The improvement coincided with higher net interest income and a wider lending margin, although noninterest expenses also increased during the quarter.
Net interest income reached $93.8 million, net interest margin rose to 4.31%, and the provision for credit losses declined to $3.6 million.
Meanwhile, Peoples is pursuing approximately $804.7 million in combined announced acquisition consideration, although the transactions remain subject to their respective closing requirements.
Elsewhere, mnninterest income excluding net gains and losses increased $1.5 million sequentially, while noninterest expenses rose $1.8 million and transaction-related losses totaled $4.8 million.
Headquartered in Marietta, Ohio, Peoples provides banking, insurance, investment and specialty financing services, with its acquisition strategy extending its regional banking operations.
Frequently asked questions
More from United States
Cineverse revenue skyrockets 110% to $26 million
Jade Biosciences reports $35 million quarterly loss
Noodles unveils $120.9 million Q3 revenue
Zai Lab antibody shows sustained biomarker suppression in phase 1 trial
Sigma Lithium posts $22.3 million gross revenue
Milestone Pharmaceuticals cuts costs 30%, extends runway




